Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.80 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.80 |
| ▸ | HPGD | P15428 | 1/20 | 0.80 |
| ▸ | PKM | P14618 | 1/20 | 0.70 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23027822 | 0.91 | LMNA (0.83) | LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD | |
| SCHEMBL23027811 | 0.89 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD | |
| SCHEMBL24325822 | 0.88 | LMNA (0.78) | LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD | |
| SCHEMBL23027798 | 0.88 | LMNA (0.78) | LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD | |
| SCHEMBL23027802 | 0.81 | LMNA (0.67) | LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD | |
| SCHEMBL23027810 | 0.81 | SMN1; SMN2 (1.00) | LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD | |
| SCHEMBL23027794 | 0.79 | LMNA (0.65) | LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD | |
| SCHEMBL17261495 | 0.78 | PKM (0.72) | LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD | |
| SCHEMBL28685921 | 0.77 | LMNA (0.62) | LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD | |
| SCHEMBL29451720 | 0.77 | PKM (0.70) | LMNASMN1; SMN2ALDH1A1L3MBTL1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202783-A1 | Use Of ADAM9 Inhibitor As Immunomodulator | CHINA MEDICAL UNIVERSITY (TW) | 2022-06-30 | — | — | US | disclosed |
| US-11357759-B2 | Composition including ADAM9 inhibitor and the use thereof | CHINA MEDICAL UNIVERSITY (TW) | 2022-06-14 | — | — | US | disclosed |
| EP-3960171-A1 | USE OF ADAM9 INHIBITOR AS IMMUNOMODULATOR | China Medical University (TW) | 2022-03-02 | — | — | EP | disclosed |
| US-20210052562-A1 | Composition Including ADAM9 Inhibitor And The Use Thereof | CHINA MEDICAL UNIVERSITY (TW) | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11357759-B2 | Composition including ADAM9 inhibitor and the use thereof | ADAM9, ADAM8, ADAM17 | LMNA 1059/4885SMN1; SMN2 2906/4885ALDH1A1 818/4885 |
| US-20220202783-A1 | Use Of ADAM9 Inhibitor As Immunomodulator | ADAM9, ADAM17, ADAM10 | LMNA 4779/4885SMN1; SMN2 3902/4885ALDH1A1 736/4885 |
| US-20210052562-A1 | Composition Including ADAM9 Inhibitor And The Use Thereof | ADAM9, ADAM8, ADAM17 | LMNA 1059/4885SMN1; SMN2 2906/4885ALDH1A1 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.